Abstract
The crosstalk of natural killer (NK) and dendritic cells (DCs) plays an important role in the induction of the tumor-specific immune response against cancer. During the last decade, our advanced understanding of the immune system led to the development of new therapeutic strategies in the field of immunotherapy and cellular immunology. However, these immunotherapeutic concepts have not been as successful as initially expected because of their inability to counteract cancer-induced immunosuppressive pathways. Some of the major difficulties of effective cellular immunotherapy are the highly immunosuppressive factors induced by tumor cells themselves or by their microenvironment. Therefore, one major challenge in immunotherapy is the question: “How to enforce NK cell & DC action under immunosuppressive conditions?” This review focuses on the current knowledge on the tumor microenvironment, the crosstalk of NK cells and DCs, as well as their deregulation in the complex interplay with the immunosuppressive tumor microenvironment. We further discuss possible strategies to minimize the negative impact of the tumor microenvironment on the immune system.
Keywords: Dendritic cells, immunotherapy, immune activation, immune suppression, natural killer cells, tumor microenvironment
Current Medicinal Chemistry
Title:The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Volume: 19 Issue: 12
Author(s): B. Jacobs and E. Ullrich
Affiliation:
Keywords: Dendritic cells, immunotherapy, immune activation, immune suppression, natural killer cells, tumor microenvironment
Abstract: The crosstalk of natural killer (NK) and dendritic cells (DCs) plays an important role in the induction of the tumor-specific immune response against cancer. During the last decade, our advanced understanding of the immune system led to the development of new therapeutic strategies in the field of immunotherapy and cellular immunology. However, these immunotherapeutic concepts have not been as successful as initially expected because of their inability to counteract cancer-induced immunosuppressive pathways. Some of the major difficulties of effective cellular immunotherapy are the highly immunosuppressive factors induced by tumor cells themselves or by their microenvironment. Therefore, one major challenge in immunotherapy is the question: “How to enforce NK cell & DC action under immunosuppressive conditions?” This review focuses on the current knowledge on the tumor microenvironment, the crosstalk of NK cells and DCs, as well as their deregulation in the complex interplay with the immunosuppressive tumor microenvironment. We further discuss possible strategies to minimize the negative impact of the tumor microenvironment on the immune system.
Export Options
About this article
Cite this article as:
Jacobs B. and Ullrich E., The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?, Current Medicinal Chemistry 2012; 19 (12) . https://dx.doi.org/10.2174/092986712800099857
DOI https://dx.doi.org/10.2174/092986712800099857 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Evaluation of Skin Permeability of Resveratrol Loaded Liposomes and Nanostructured Lipid Carriers using a Skin Mimic Artificial Membrane (skin-PAMPA)
Drug Delivery Letters Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry The Effects of Colchicum baytopiorum on Regulatory Genes of Apoptotic and Autophagic Cell Death in HeLa Cells
Current Pharmaceutical Biotechnology Neural Stem Cells - A Promising Potential Therapy for Brain Tumors
Current Stem Cell Research & Therapy Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors
Central Nervous System Agents in Medicinal Chemistry An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targeting of Apoptotic Pathways: Novel Aspects in Pancreatic Cancer
Current Pharmaceutical Biotechnology Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine RNAi in Clinical Studies
Current Medicinal Chemistry Antioxidant Effect of a Nitrated Cyclic Nucleotide Functioning as an Endogenous Electrophile
Current Topics in Medicinal Chemistry Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors
Current Topics in Medicinal Chemistry Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry